Press releases
- GSK announces results evaluating its investigational monoclonal antibody, otilimab, for the treatment of hospitalised adult patients with COVID-19
- ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months
- Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
Tweets from GSK US
-
GSKUS @GSKUS
GM-CSF in the immune response to #COVID19 may be more prominent in patients over 70, putting them at an increased risk for serious complications related to #COVID-19. Watch this video for more about GM-CSF: gsk.to/37IvR1S
about 2 hours ago -
GSKUS @GSKUS
#News for #investors and #media. We're moving ahead with an extension to our OSCAR study for the potential treatment of hospitalized patients with #COVID19. Learn more: gsk.to/3sqLmDI
about 3 hours ago -
GSKUS @GSKUS
#News for #investors and #media: We’ve announced results from our OSCAR study for the potential treatment of hospitalised patients with #COVID19 and are moving forward with an extension of the study in patients 70 years and older: gsk.to/3aSF3Tu
about 3 hours ago
